Study Uncovers Potential Treatment for Parkinson’s-Related Dementia

About half of people diagnosed with Parkinson’s disease will develop dementia within 10 years, a condition that deeply affects not only individuals but also their families and caregivers. Parkinson’s disease dementia can lead to memory loss, confusion, hallucinations, and mood changes—with very few treatments currently available to slow its progression. 💊 Could a Common Cough Medicine Help? A 12-month clinical trial, led by Dr. Stephen Pasternak at Lawson Health Research Institute and Western University, explored whether Ambroxol, a medication commonly used in Europe for respiratory conditions, could slow cognitive decline in people with Parkinson’s disease dementia. 🧪 Study at a Glance 55 participants with Parkinson’s dementia took part. Half received Ambroxol daily; the other half received a placebo. The study tracked memory, psychiatric symptoms, and GFAP, a blood marker linked to brain cell damage. Results were published in JAMA Neurology. 🔍 Key Findings ✅ Ambroxol was safe and well-tolerated, reaching therapeutic levels in the brain. ⚖️ Psychiatric symptoms worsened in the placebo group but stayed stable in the Ambroxol group. 🧬 People with a GBA1 gene variant—a known risk factor for Parkinson’s—showed improved cognitive performance on Ambroxol. 🧠 The marker of brain cell damage (GFAP) increased in those on placebo but remained stable with Ambroxol, hinting at potential brain protection. 🧬 Why Ambroxol Might Work Ambroxol boosts the activity of glucocerebrosidase (GCase), a crucial enzyme produced by the GBA1 gene. In people with Parkinson’s, GCase is often deficient, causing toxic waste buildup in brain cells. By enhancing this enzyme, Ambroxol may help protect the brain from further damage. Dr. Pasternak first learned about Ambroxol while studying treatments for Gaucher disease, a rare childhood disorder linked to the same enzyme deficiency. He is now applying those insights to Parkinson’s research. 🇨🇦⚖️ Approval Status Although Ambroxol is approved in Europe and has a strong safety record—including during pregnancy and at high doses—it is not yet approved for any use in Canada or the U.S. 🧭 Looking Ahead “Current therapies treat the symptoms but don’t slow the disease. Ambroxol could be a step toward changing that.” – Dr. Stephen Pasternak This early trial, funded by the Weston Family Foundation, lays the groundwork for larger studies. A new trial focused specifically on cognitive outcomes is planned for later this year. ❤️ Why This Matters Parkinson’s dementia is life-altering—not just for individuals, but for the people who love and care for them. While more research is needed, this study offers a promising path forward in a space where few treatment options currently exist.